ArticleAmerican journal of epidemiology2026
Machine learning methods for estimating personalized treatment effects-insights on validity from two large trials.
Article in American journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Machine learning (ML) methods have the potential to improve precision medicine by estimating personalized treatment effects. However, formal validation of these methods remains limited, leaving their reliability in empirical settings largely uncertain. In this study, we evaluated the internal and external validity of 17 causal heterogeneity ML methods-including metalearners, tree-based methods, and deep learning methods-using data from two large randomized controlled trials: the International Stroke Trial (n = 19 435) and the Chinese Acute Stroke Trial (n = 21 106). We assessed performance using three visual-based metrics and three quantitative metrics. Our analysis found that none of the ML methods consistently demonstrated reliable performance, neither internal nor external. Heterogeneous treatment effects estimated from training data failed to generalize to the test data, even in the absence of distribution shifts. These results raise concerns about the current applicability of ML models in precision medicine and highlight the need for more robust validation techniques to ensure generalizability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.